Moderate intensity aerobic + resistance exercise did not lead to superior pain and function outcomes in patients with hip OA, compared with resistance exercise alone.

The following is a summary of "Mental Health Status and Quality of Life is Not Improved in Amputees Following Targeted Muscle ...

The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

The primary endpoint of the study was analgesic efficacy, as measured by the Pain Numeric Rating Scale (NRS) Area Under the Curve for 2 to 48 hours (AUC 2-48) following dosing of cebranopadol vs ...

Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

ALLEVIATE-2 Phase 3 Results: Significant Pain Reduction in Cebranopadol-Treated ... as measured using the Pain Numeric Rating Scale (NRS) Area Under the Curve for two to 48 hours (AUC 2-48 ...